Tenuate, the brand name for diethylpropion, was pulled from the market for commercial reasons, not because regulators forced it off shelves in the United States. The FDA reviewed its records and confirmed that Tenuate was “not withdrawn from sale for reasons of safety or effectiveness.” However, the story is more complicated than a simple business decision. In Europe, regulators took a much harder line, ordering the drug’s marketing authorization revoked in January 2023 over serious safety concerns. Together, these two developments effectively ended Tenuate’s run as a prescription weight loss drug.
What Happened in the U.S.
Both formulations of Tenuate, the 25 mg immediate-release tablet and the 75 mg extended-release tablet (Tenuate Dospan), appeared on the FDA’s Discontinued Drug Product List after the manufacturer, Nostrum Labs, stopped marketing them. The FDA’s official determination was clear: the products were not pulled for safety or efficacy reasons. This means generic versions of diethylpropion could still legally be approved and sold, though availability has become extremely limited in practice.
Why a manufacturer stops producing a drug without a regulatory mandate usually comes down to economics. Low demand, thin profit margins, rising production costs, or the arrival of newer competitors can all make an older product financially unviable. For Tenuate, which was only approved for short-term use of “a few weeks,” the commercial landscape shifted dramatically as newer long-term weight loss medications entered the market.
Why Europe Banned It Outright
The European Medicines Agency took a far more aggressive approach. After a formal review, the agency recommended withdrawing marketing authorization for all diethylpropion-containing medicines. The European Commission made this decision legally binding across all EU countries on January 13, 2023.
The core problem was how the drug was actually being used versus how it was supposed to be used. Regulators found that patients were taking diethylpropion for longer than the recommended three-month maximum, which raised the risk of serious side effects. It was also being prescribed to patients with a history of heart disease or psychiatric disorders, populations that faced elevated dangers from the drug. The EMA concluded that this pattern of real-world misuse made the risks unacceptable, citing four specific concerns: pulmonary arterial hypertension (dangerously high blood pressure in the lung arteries), cardiovascular disease, dependency, and psychiatric disorders. Harm to unborn babies in pregnant users was also flagged.
The Safety Concerns Behind the Decision
Diethylpropion is chemically similar to amphetamines, and it carried many of the same risks. The FDA’s own prescribing label acknowledged that prolonged use could cause dependence, with a withdrawal syndrome when patients stopped taking it. There were reports of patients escalating their doses far beyond what was prescribed. Abruptly stopping the drug after prolonged high-dose use caused extreme fatigue and depression.
At its worst, chronic overuse could produce symptoms that looked like schizophrenia: severe skin problems, marked insomnia, irritability, hyperactivity, and personality changes. These weren’t theoretical risks. They were documented in the drug’s FDA label as “manifestations of chronic intoxication.” Diethylpropion was classified as a Schedule IV controlled substance by the DEA, placing it in the same category as drugs recognized to have real, if moderate, abuse potential.
The cardiovascular risks were particularly concerning. The prescribing information warned that extended use, higher-than-recommended doses, or combining diethylpropion with other appetite suppressants could contribute to heart valve disease. Pulmonary arterial hypertension, a rare but life-threatening condition, was also linked to the drug. One published case documented a 27-year-old woman who developed the condition after just a short course of diethylpropion. She carried a genetic mutation that made her susceptible, and researchers concluded the drug triggered the disease in her case. Other patients without that specific mutation also developed the condition, suggesting multiple genetic factors could make someone vulnerable.
Did It Even Work Well Enough?
Diethylpropion did produce meaningful weight loss in clinical trials. In one randomized, placebo-controlled study, patients taking the drug lost an average of 9.8% of their body weight over six months, compared to 3.2% in the placebo group. After a full year, the diethylpropion group averaged 10.6% weight loss. Notably, that study found no differences in blood pressure, heart rate, or psychiatric evaluations between the drug and placebo groups, and the researchers concluded it appeared safe in a “well-selected population.”
The catch is in that phrase “well-selected population.” Under carefully controlled trial conditions with screened participants, the drug looked reasonable. But in the real world, patients weren’t being carefully selected. They were using it longer than a few weeks, sometimes with heart conditions or psychiatric histories that should have been disqualifying. The gap between how the drug performed in trials and how it was actually prescribed is what ultimately drove European regulators to pull it. The FDA’s prescribing label itself acknowledged this tension, noting that obesity is “measured in years” while most studies only lasted a few weeks, making the long-term impact of the drug essentially unknown.
What Replaced Tenuate
The weight loss medication landscape looks completely different today. The FDA has approved six drugs for long-term (chronic) weight management: orlistat (Xenical, Alli), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound). The last two, both injectable GLP-1 receptor agonists, produce significantly greater weight loss than older appetite suppressants ever achieved and are approved for ongoing use rather than just a few weeks.
Phentermine, another older stimulant-type appetite suppressant, remains available for short-term use and is sometimes prescribed off-label for longer periods. But the trend in obesity medicine has moved decisively toward drugs with stronger efficacy data, better safety profiles, and approval for the kind of long-term treatment that a chronic condition like obesity actually requires. In that context, a drug like Tenuate, with modest short-term approval, real abuse potential, and serious cardiovascular red flags, simply had no competitive reason to exist.